Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Temozolomide in Advanced Melanoma
NCT03422445Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in melanoma, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03422445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422445.